The company announced Bioma4me has implemented
SOPHiA DDM™ to support its rare disorder testing
capabilities
BOSTON and ROLLE, Switzerland, Jan. 25,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company in the healthcare space and a
leader in data-driven medicine, today announced that Bioma4me, a
Brazil-based company focused on
genetic sequencing to drive precision medicine to the Brazilian
population, is now live on the SOPHiA DDM™ Platform. The company
will use SOPHiA GENETICS' technology to advance and streamline its
genetic testing capabilities.
Bioma4me is a leader in Brazil
in providing personalized medicine, supported by genetic analysis
of each individual, offered at an affordable cost, with great
precision and in the shortest possible time.
"We are thrilled to announce our collaboration with SOPHiA
GENETICS, a leader in AI to further precision medicine. This
partnership marks a significant milestone in the journey of
scientific discovery and innovation for Bioma4me," said
Rafael Malagoli Rocha, PhD, Sócio
Diretor, Bioma4me. "This collaboration is a fusion of expertise in
order to drive forward the frontiers of human genetics and
metagenomics in Latin America.
Bioma4me is committed to unlocking new possibilities and advancing
the field of oncology, microbiome, and genetic diseases in general,
bringing hope and answers to our community. We celebrate this
partnership as a testament to what can be achieved in the novelties
in data-driven medicine."
Through the SOPHiA DDM™ Platform, Bioma4me will be able to
apply its next-generation sequencing (NGS) expertise to the whole
exome. The SOPHiA DDM™ Platform will help the company streamline
and expedite data analysis, which will save valuable time for
clinical researchers and support the enablement of precision
medicine for customers.
"We believe in advancing the use of precision medicine globally,
supporting researchers and clinicians with our AI-based SOPHiA
DDM™ Platform to help advance cancer research and provide
better health outcomes worldwide," said Ricardo Mendonca Filho, PhD., Managing Director,
LAPAC, SOPHiA GENETICS. "By using our platform, Bioma4me will be
able to enhance and expedite its testing capabilities to deliver a
comprehensive panel for its customers."
The SOPHiA DDM™ Platform will enable Bioma4me fast
turnaround time for results. Additionally, Bioma4me will have full
ownership over its data and access to the SOPHiA GENETICS
decentralized global network, helping to continuously
advance its researchers' capabilities and knowledge base.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on X, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care for life sciences research. It is the creator of the SOPHiA
DDM™ Platform, a cloud-native platform capable of analyzing data
and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-supports-genetic-testing-in-brazil-302044884.html
SOURCE SOPHiA GENETICS